Dr. Reddy's Laboratories Ltd Q1FY22 consolidated PAT at Rs. 380.4 Cr

The company posted net profit of Rs.594.6 crores for the period ended June 30, 2020.

Aster DM Healthcare completes acquisition of 5% stake in Quality Care India

The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow

Medanta to set up a 400-bed super specialty hospital in Guwahati

The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital

Morepen to launch new fatty lever drug ‘Resmetirom’

Merck to acquire US Biopharma firm SpringWorks Therapeutics for enterprise value of $3.4 billion

Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide

Biocon Biologics receives positive CHMP opinions for biosimilar Denosumab in Europe

The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited

Dr. Lal Path Labs posts Q4 FY25 consolidated PAT at Rs. 154.8 Cr

The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025

We’re working at full force to put Bayer back on a profitable growth path: Bill Anderson, CEO, Bayer

Bayer expects 2025 to be the most difficult year of its turnaround

Syngene International posts Q4 FY25 consolidated profit at Rs. 183.3 Cr

Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time

Lupin receives USFDA approval for Tolvaptan Tablets

Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease